Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 8/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CDC42 | P60953 | 1/20 | 0.42 |
| ▸ | RAC1 | P63000 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604674 | 1.00 | AKR1C2 (0.49) | AKR1C2AKR1C3PTGS1AKR1C1HTT | |
| SCHEMBL7604678 | 1.00 | AKR1C2 (0.49) | AKR1C2AKR1C3PTGS1AKR1C1HTT | |
| SCHEMBL6372113 | 0.84 | ADRA1A (0.54) | AKR1C2AKR1C3PTGS1AKR1C1HTT | |
| SCHEMBL6372116 | 0.84 | ADRA1A (0.54) | AKR1C2AKR1C3PTGS1AKR1C1HTT | |
| SCHEMBL6372120 | 0.84 | ADRA1A (0.54) | AKR1C2AKR1C3PTGS1AKR1C1HTT | |
| SCHEMBL6366172 | 0.80 | KMT2A (0.41) | SMN1; SMN2TSHR | |
| SCHEMBL6366174 | 0.80 | KMT2A (0.41) | SMN1; SMN2TSHR | |
| SCHEMBL6366177 | 0.80 | KMT2A (0.41) | SMN1; SMN2TSHR | |
| SCHEMBL6372641 | 0.79 | PTGS2 (0.57) | AKR1C2AKR1C3PTGS1PTGS2CDC42 | |
| SCHEMBL16956030 | 0.76 | ADRA1A (0.42) | HTTHSD17B10TSHRADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-14 | — | — | US | disclosed |
| US-6255301-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | F2, SERPINC1, FGB | AKR1C2 4246/4885AKR1C3 3984/4885PTGS1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.